Introduction
Immune escape by tumors is a fundamental aspect of disease progression resulting from immunoediting of tumors as they interact with the host immune system 1, 2 . Key to this process from a therapeutic standpoint is that tumors are selected to engender a tolerogenic microenvironment that actively suppresses the ability of the immune system to mount an effective response 3 . Ongoing progress in understanding the cellular and molecular mechanisms that govern the pathological state of tumor immune tolerance has revealed several protein targets which provide the potential for therapeutic intervention 4 . One central player is the immunomodulatory enzyme indoleamine 2,3-dioxygenase, IDO1, formerly known as IDO before the discovery of a second isoform 5, 6 . IDO1 can contribute to immune escape when expressed directly in tumor cells or when expressed in immunosuppressive antigen presenting cells such as tolerogenic dendritic cells or tumor associated macrophages 7, 8 . For both cases, experimental results suggest that IDO1 inhibition may restore an effective antitumor immune response and thus provide a method to treat malignant diseases in combination with chemotherapeutic agents and/or immunotherapy-based strategies 9 . In fact, there are currently three drugs in clinical trials testing IDO1 inhibition as a strategy for the treatment of cancer 10 . Clearly there is an interest and a need for further development of potent IDO1 inhibitors to adequately address this therapeutic opportunity 11, 12 .
IDO1 is an extrahepatic, tryptophan (Trp) metabolizing enzyme, [13] [14] [15] which catalyzes the initial and rate-limiting step along the kynurenine pathway. The oxidative metabolism of Trp by IDO1 involves the coordination of molecular oxygen to a ferrous heme iron and its subsequent addition across the C-2/C-3 bond of the indole ring. Two alkylperoxy transition or intermediate states resulting from dioxygen insertion to C-2 or C-3 carbon of the indole ring ( Figure 1 , compound 1 and 2) have been proposed 13, [16] [17] [18] . Here we sought to rationally design a new family of IDO1 inhibitors by mimicking the alkylperoxy species as illustrated in Figure 1 , in which one oxygen atom of the peroxo moiety is substituted with an electronegative atom, N (compound 3). To simplify compound 3, the alkylperoxy moiety is further reduced to Ar-C-X-Y, where Ar is an aryl ring and C is a linker containing a carbon moiety (such as methylene or carbonyl). In related work, two previously reported IDO1 inhibitors in the scientific literature demonstrate a similar theme in their inhibitor design: The hydroxyamidines reported in 2009
by Incyte 19 and the recent report of alkylhydrazine derivative inhibitory activity by Ching et al. 20 .
Neither of these reports discussed the potential mimicry of the proposed alkylperoxy intermediate or related rational design idea. Contemporaneous with our studies, O-alkylhydroxylamine IDO1 inhibitors were reported in the patent literature by NewLink Genetics 21 . With the rise of chemical library screening for drug lead development, mechanism-based rational drug design ideas are less frequently used, but the current work illustrates there is still merit in their use as they proved a simple and efficient way to identify a new IDO1 inhibitor lead. 
Results and Discussion
Discovery of New Structural Class of IDO1 Inhibitors. To explore this rational drug design idea, we screened commercially available compounds with a general structure of Ar-X-Y or Ar-C-X-Y (Table 1) . Gratifyingly, a screen of a few dozen commercial compounds yielded several micromolar or sub-micromolar potency molecules. Similar to the recent report from the Ching group 20 , phenylhydrazine was found to be a highly potent inhibitor of IDO1. This is not surprising since phenylhydrazine has been found to interact with other heme-containing proteins, such as hemoglobin, 22 cytochrome P450, 23 catalase 24 and myoglobin 25 . In fact, phenylhydrazine can be oxidized by heme iron to generate phenyl radicals that can subsequently react to covalently modify the heme prosthetic group 26 . Although we did not see any signs of irreversible inhibition by phenylhydrazine, we chose to focus our efforts on O-benzylhydoxylamine, the second best inhibitor with an IC50 of 0.90 M, as we were more interested in developing a reversible inhibitor of IDO1. Nonetheless, all the compounds in Table 1 represent a new class of IDO1 inhibitors: alkylperoxy mimics. The therapeutic potential of IDO1 inhibition, as well as the commercial availability and sub-micromolar level potency of these compounds, made this discovery an important opportunity. Our efforts at developing peroxy structural mimics, in particular, optimizing the O-alkylhydroxylamine structural class, are described below. 
Ph-C(=O)-NH-OH 16
Ph-CH2-NH-NH2 71
a IC50 values are based on single point inhibition curves run once for each compound, but repeated 2x
for the most potent compounds (initial IC50 values below 1.0 M). These results are reported as the averages ± SD.
Chemistry
The O-alkylhydroxylamine derivatives were synthesized from the analogous alcohol through a one pot process involving the Mitsunobu reaction with N-hydroxyphthalimide 27 and subsequent deprotection isolated as their hydrochloride salts. Alcohols that were not commercially available were synthesized via reduction of the appropriate aldehyde with NaBH4 (Scheme 2). 
Scheme 1. Mitsunobu Reaction to Convert Alcohols to O-Alkyl Hydroxylamines

Results and Discussion
IDO1 Inhibition by O-Alkylhydroxylamines.
In an effort to further optimize the O-benzylhydroxylamine lead, we explored two general modifications of the O-benzylhydroxylamine structure: (1) alteration of the carbon linker between the aryl ring and the hydroxylamine group; (2) substitution of the aryl ring ( Figure 2 ).
Figure 2. Two Modifications of O-Benzylhydroxylamine Lead Compound
Alternation of the carbon linker between the aryl ring and the peroxy mimic moiety
Linker length and flexibility was explored with the compounds shown in Table 2 . It quickly became clear that any modifications made to the carbon linker in the lead compound resulted in a dramatic decrease in inhibitor potency. Attempts at rigidifying the hydroxylamine moiety in the benzylic position (compounds 3, 4 and 6) were unsuccessful as well. a IC50 values are based on single point inhibition curves run once for each compound except for the lead compound which was repeated 2x. These results are reported as the average ± SD.
Substitution of the Aryl Ring
Derivatization of the O-benzylhydroxylamines via substitution on the aromatic ring initially explored potential interactions with the amino acid residues located in the active site (C129, S167, Y126) by adding hydrogen donating or accepting substitutions to the phenyl ring. Previous work from our laboratory had successfully exploited these interactions in the optimization of the phenyl-imidazole structural series 29 . However, addition of a hydroxyl group at the ortho (29) or para (31) position substantially reduced inhibition (Table 3) . Likewise, ortho, meta, or para-substitution with a methoxy also proved deleterious (24, 26 and 30). Halogen substitution was the only successful modification that increased inhibitor potency, which contrasts with the results of the phenyl-imidazole study 29 . Addition of iodine, bromine, chlorine or trifluoromethyl substituents to either ortho, meta or para positions of Obenzylhydroxylamine (8-15) proved beneficial with the greatest gain in IDO1 inhibitor potency seen with halogens in the meta position. In contrast to other halogen substitutions, the more electronegative fluorine containing inhibitors (15, 16 and 18) were essentially equipotent or slightly less potent than the lead. 37, 38 . A more traditional explanation of simple favorable hydrophobic interactions by the halogens seems less likely due to the weaker activity seen with 3-methyl (22) and 4-isopropyl (28) , which are considered roughly isosteric with chlorine and iodine respectively 39 .
Disubstitution of the Aryl Ring
Synergistic effects of multiple substituents were also explored with a particular focus on maximizing the halogen benefits. However, as depicted in Table 4 , minimal additive effects were observed when combining beneficial substitutions from the monoaryl system. None of the disubstituted derivatives was more potent than the most potent monosubstituted derivatives, i.e. the C-3 substituted compounds. Given the perplexing results, especially the contradictions with the phenyl-imidazole work, we further explored the binding mechanism of the monoaryl hydroxylamines, including the lead compound, a monosubstituted derivative (8) and a disubstituted derivative (40) , by UV-Vis absorption spectroscopic studies. As shown in Figure 3B , in the absence of inhibitors, the deoxy ferrous enzyme exhibits Soret and Q band at 427 and 556 nm, characteristic for a typical five-coordinate high-spin heme species.
Binding of the lead compound, In addition to the deoxy enzyme, we also studied inhibitor binding to the CO-bound ferrous enzyme, where CO was used as a surrogate for O2. The CO-bound IDO1 exhibits Soret and Q band at 421 and 538/568 nm, typical for a CO bound six-coordinate low-spin heme species ( Figure 3C ). The addition of the lead compound resulted in a spectrum similar to that of the inhibitor-bound deoxy species shown in (B), indicating that inhibitor binding prevents CO binding to the heme iron. In contrast, the addition of 8 or 40 led to a spectrum, consistent with a mixture of inhibitor-bound deoxy spectrum (B) and CO-bound spectrum (C), indicating that inhibitor binding partially prevents CO binding to the heme iron.
Comparative studies suggested that the affinity of these inhibitors towards the ferric enzyme ( Figure   3A ) is much weaker than the ferrous enzyme. 
Modeling of Monoaryl Hydroxylamine Binding to Guide Drug Development
With confirmation that the monoaryl hydroxylamine compounds inhibit IDO1 by coordinating to the heme iron, we then turned to docking studies using Gold (v5.1) to determine their potential binding modes ( Figure 4 ). Unsubstituted monoaryl inhibitor, O-benzylhydroxylamine, was predicted to have two equally plausible binding modes: in the interior of the cavity near residues F163 and S167, or in the entrance of the cavity between residues F226 and the heme propionate group. Ortho-substituted inhibitors (C-2 substitution, Figure 5 ) were predicted to bind in the back of the cavity (blue structure in Figure 4 ), while the para-substituted inhibitors (C-4 substitution, Figure 5 ) appeared to preferentially bind in the cavity entrance (magenta structure in Figure 4 ). The two outliers to this trend were compound 29 (2-OH) and compound 31 (4-OH). For compound 31, docking predicted the formation of a hydrogen bond with the S167 in the back of the cavity, while for compound 29 docking suggested hydrogen bonding with the heme propionate in the front of the cavity. Nonetheless, assessment of the inhibition data does not support that either of these predicted hydrogen bonds enhance the binding affinity in comparison with the halogenated derivatives; this stands in contrast to earlier reported hydroxyl-substituted 4-phenyl-imidazole inhibitors 29 . Docking of the meta substituted analogs to IDO1, however, did not define a consistent binding mode as the aryl ring could be equally positioned either in the back or the entrance of the cavity (C-3 substitution, Figure 5 ). 
Detailed Enzyme Inhibition Studies
As further confirmation of the inhibitory characteristics of the hydroxylamine structural class, inhibitory constants (Ki) were determined for two of the most potent hydroxylamine inhibitors. Analysis
showed Ki values of 164 and 154 nM for two O-alkylhydroxylamines, 8 and 9, respectively These potency values yield ligand efficiencies of 0.93 for both compounds 40 41,42 . Given the strong correlation between successful drugs and high ligand efficiencies, the O-alkylhydroxylamines represent a promising class of IDO1 inhibitors 43 . Based on Lineweaver-Burk graphical analysis, both molecules demonstrated 
Selectivity Studies
The simplicity of the O-alkylhydroxylamines makes concerns about their selectivity warranted, especially given their primary mechanism of attraction to IDO1, heme iron binding. To analyze the selectivity of two of the top compounds, 8 and 9, two additional heme iron containing enzymes, catalase and CYP3A4, were screened for inhibition. As noted in Table 5 , neither 8 nor 9 showed inhibition of catalase; perhaps this is not surprising given catalase's small natural substrate, hydrogen peroxide, however, this result does demonstrate that the inhibitory activity of these compounds is not attributable to an indirect effect on the catalase in the reaction mixture that is required to protect IDO1 from oxidative damage. CYP3A4 was inhibited at the low micromolar level by both 8 and 9. However, this is still 22-and 48-fold less potent than IDO1 based on the IC50 values for 8 and 9, respectively. This suggests that the O-alkylhydroxylamines are selective, but they do demonstrate some promiscuity and as studies advance, they will need to be closely monitored for off-target activity. 
Cell-based Assays
To assess the therapeutic potential of the hydroxylamine structural class, two of the most potent compounds, 8and 9, were tested for cell-based activity in two cell systems: HeLa, expressing native human IDO1 induced with IFN, and Trex, expressing recombinant human IDO1 induced with doxycycline (Table 7 ; graphs found in Supplementary Data, Figure S4 ). Both compounds demonstrated nanomolar level activity in both the HeLa and Trex cell lines. Compounds 8 and 9 were more potent in the cell-based assay than in the isolated enzyme assay. Although such a result is generally considered inconsistent with normal drug activity, this irregularity has been seen repeatedly with IDO1 studies 19, 46 and has been attributed to deficiencies in the isolated enzyme assay, and specifically problems with controlling IDO1 redox activity. Figure S4 ). Assessment of impact of human serum protein binding indicated a substantial reduction in inhibitory activity for one of the compounds, 8, while the inhibitory activity of 9 was relatively unaffected (see Supplementary Data, Figure S5 ). This analysis indicates that it should be possible to develop O-alkylhydroxylamine inhibitors that are not unduly compromised by serum protein binding.
Cumulatively, the cell-based potency and the cytotoxicity studies dramatically illustrate the therapeutic potential for the hydroxylamines. To the best of our knowledge, there are only two other structural classes reported to date with similar nanomolar-level cell-based potency 19, 32, 33, 46 and both of these have been developed for clinical evaluation. Translating enzymatic potency to cell-based potency has been a major roadblock to inhibitor development for other structural classes such as the naphthoquinones 47 . Furthermore, two Oalkylhydroxylamine derivatives, 8 and 9, demonstrated exceptional potency on par with the two compounds INCB024360 48 and NLG919 49 that are currently being evaluated in clinical trials. Given the exciting potential of these rather simple molecules to meet the burgeoning interest in IDO1 inhibition for both biological investigations of the kynurenine pathway and therapeutic applications, we believe that the O-alkyl hydroxylamines will be a useful structural class of inhibitors.
Experimental Section
Chemical synthesis.
General Procedures.
All reactants and reagents were commercially available and were used without further purification unless otherwise indicated. Anhydrous THF was freshly distilled from Na and benzophenone. All reactions were carried out under an inert atmosphere of argon or nitrogen unless otherwise indicated.
Concentrated refers to the removal of solvent with a rotary evaporator at normal water aspirator pressure (10°C/min) and finally holding at 250°C for 7 min. The free hydroxylamine compounds were generated by treating the hydrochloride salts with saturated NaHCO3 and extracting with EtOAc. All compounds were found to be >95% purity by elemental analysis, GC, or HPLC as indicated.
General Synthesis of O-Alkyl Hydroxylamines.
To a solution of alcohol (1 mmol) in freshly distilled THF (5 ml) was added triphenylphosphine ( 
O-(3-Phenyl-2-propenyl)-1-hydroxylamine hydrochloride (2).
Synthesized from 3-phenyl-2-propen-1-ol according to the general procedure to afford 2 as white crystals in 90% yield. 1 
O-(1,2,3,4-Tetrahydro-1-naphthalene)-hydroxylamine hydrochloride (3).
O-(2,3-Dihydro-1H-inden-2-yl)-hydroxylamine hydrochloride (4).
O-(2-3-Dihydro-1H-inden-1-yl)hydroxylamine (6). Synthesized from 2,3-dihydro-1H-inden-ol
according to the general procedure to afford 6 as white crystals in 78% yield. Mp=150. Biochemical assays. Recombinant human IDO1 was expressed and purified as described. 50 Inhibition assays to determine IC50 and Ki values were performed in a 96-well microtiter plate as described by
O-(3-Phenylpropyl)-hydroxylamine hydrochloride (7).
Littlejohn et.al. 50 with some modification. Under these assay conditions, we have previously determined that the recombinant hIDO1 follows Michaelis-Menten kinetics 51 . Briefly, the reaction mixture contained 50 mM potassium phosphate buffer (pH 6.5), 40 mM ascorbic acid, 400 g/ml catalase, 20 Spectroscopic measurements. The UV-Vis spectra were obtained at room temperature using a UV2401 spectrophotometer (Shimadzu Scientific Instruments, Inc., Columbia, MD) with a slit width of 1 nm in a 1 cm path-length quartz cuvette. The proteins (5 M) were buffered with a 100 mM pH of 7.4
Tris buffer. The deoxy samples were prepared by injecting ~10-fold excess sodium dithionite into the protein samples pre-purged with nitrogen gas with a gas-tight syringe. The CO adducts were prepared by adding 200 l CO gas (1 atmosphere) into the deoxy samples. proportional to cell number, was determined by reading the absorbance at 570 nm on a plate reader.
Graphs of cell viability curves were generated using Prism v.5.0 (GraphPad Software, Inc.).
Docking calculations.
Small molecules were constructed in MOE V2011.1 (Chemical Computing
